Search
systemic necrotizing vasculitis
Management:
- lower dose cyclophosphamide in initial treatment of older patients associated with fewer serious adverse effects without difference in relapse rates
- maintenance therapy
- azathioprine
- rituxumab may be better than azathioprine for ANCA-associated vasculitis
- rituxumab used for induction in patients with ANCA-associated vasculitis
- prognaosis: relapse common
Related
autoimmune vasculitis
Specific
allergic angiitis & granulomatosis of Churg-Strauss; eosinophilic granulomatosis with polyangiitis (EGPA)
classic polyarteritis nodosa (PAN)
granulomatosis with polyangiitis; Wegener's granulomatosis
microscopic polyangiitis
References
- Coblyn JS
Lower-Dose Therapy Is Associated with Fewer Serious Adverse
Events in Elders with Systemic Necrotizing Vasculitis.
NEJM Journal Watch. May 5, 2015
Massachusetts Medical Society
(subscription needed) http://www.jwatch.org
- Pagnoux C, Quemeneur T, Ninet J et al
Treatment of systemic necrotizing vasculitides in patients
aged sixty-five years or older: Results of a multicenter,
open-label, randomized controlled trial of corticosteroid
and cyclophosphamide-based induction therapy.
Arthritis & rheumatology 2015 Apr; 67:1117.
PMID: 25693055